Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Bristol Myers Squibb International Corporation
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 1/2a, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 02, incorporating Protocol Amendment 02 (Version 1.0, Date 17-Oct-2007) and 03 (Version 1.0, Date 26-Nov-2007). And Pharmacogenetics Blood Sample Amendment 01 (Version 3.0, Date 14-Aug-2007)
• Primary Phase 1 Objective: To determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended Phase 2 dose of BMS-753493 administered as a 3 to 5 minute bolus i.v. infusion ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 2 Randomized, Parallel-Arm Study of Oral Direct Factor Xa-Inhibitor Apixaban and Low Molecular Weight Heparin or Fondaparinux With A Vitamin K Antagonist In Subjects With Acute Symptomatic Deep-Vein Thrombosis. Revised Protocol 02, Incorporates Amendments 02, 04 and Administrative Letter dated 14-Apr-2006; + Pharmacogenetics Blood Sample Amendment version 01 dated 29-June-2005
To assess efficacy and safety of 3 doses of apixaban 5 mg BID, 10 mg BID and 20 mg QD versus conventional treatment with low molecular weight heparin (LMWH) or fondaparinux and vitamin K antagonist (V...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A first-in-human study to explore the BMS-986158 study drug for patients with advanced cancer
To assess the safety and tolerability and to define the dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of BMS-986158 as monotherapy for subjects with selected advanced solid tumors.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Comparative Study of Chronic Hepatitis B Subjects Treated with Entecavir Plus Tenofovir Combination Therapy vs Entecavir Monotherapy in Adults who are Treatment-Naïve to Nucleosides and Nucleotides: The BE-LOW Study. Revised Protocol 01, incorporating protocol amendment 02 (Version 2.0, Date 22-Jan-07)
To compare the proportion of subjects in each treatment group who achieve HBV DNA < 50 IU/mL (approximately 300 copies/mL) by PCR at Week 96 of treatment using the Roche COBAS® TaqMan HBV Test for use...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
This clinical research study will assess the effectiveness (how well it works), safety, tolerability (how well the body stands the drug) and blood levels of combined doses of BMS-663068, Raltegravir and Tenofovir. Este estudio de investigación clínica evaluará la eficacia (lo bien que funciona), la seguridad,la tolerabilidad (lo bien que el cuerpo "soporta" el medicamento) y los niveles en sangre de dosis combinadas de BMS-663068, Raltegravir y Tenofovir
To assess the efficacy of four doses of BMS-663068 by determining the proportion of subjects with plasma HIV-1 RNA < 50 c/mL at Week 24 To assess the safety of four doses of BMS-663068 in treatment-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase I/II Trial of BMS-754807 in Combination with Trastuzumab (Herceptin®) in Subjects with Advanced or Metastatic Her-2-positive Breast Cancer Revised Protocol Number 03 (version 4.0, dated 19-May-10), incorporating Administrative Letters 01, 02 and 03; and Amendment 03, 04 and 05 + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific (version 1.0 dated 13-Aug-08)
The dose escalation part will determine the maximum tolerated dose (MTD) and a recommended Phase II dose (or dose range as appropriate) of BMS-754807 administered orally on a once daily schedule in co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects with Melanoma Estudio de seguirdad y eficacia de múltiples regímenes de administración de la combinación Nivolumab más Ipilimumab en sujetos con melanoma
The primary objective is to evaluate the difference in safety between the FRC product (BMS-986214) relative to sequentially administered nivolumab 1 mg/kg and ipilimumab 3 mg/kg as measured by the inc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase 1/2, Ascending Multiple-Dose Study to Evaluate the Safety, Efficacy and Pharmacokinetics of BMS-753493 in Subjects with Advanced Cancer. Revised Protocol 04, incorporating Protocol Amendment 02 (v1.0, Date 16-Oct-2007), 03 (v1.0, Date 26-Nov-2007), 04 (v2.0, Date 20-May-2008), and 05 (v3.0, date 24-Mar-2009). And Pharmacogenetics Blood Sample Amendment 01 - Site specific (version 2.0, Date 16-Jul-2007)
Phase 1 Primary Objective: • To determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT) and recommended Phase 2 dose of BMS-753493 administered as a 3 to 5 minute bolus i.v. infusion ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to Imatinib
The primary objective of this study is to further assess the safety of dasatinib when administered 100 mg QD in CP CML subjects or 140 mg QD in AD CML or Ph+ ALL subjects as measured by the incidence ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Bristol Myers Squibb International Corporation
MAJ Il y a 5 ans
Study for the assessment of Safety and Efficacy of treatment with the study medication Ipilimumab in comparison with treatment with Pemetrexed. Affected patients are patients with recurrent / Stage IV NSCLC where the disease did not progress (growth of tumour) after 4 cycles of Chemotherapy treatment with platinum Chemotherapy. Patients are distributed by random to one of the two treatments, but will be aware which treatment they receive Studio per la valutazione dell’efficacia e sicurezza del trattamento con il farmco sperimentale Ipilimumab in confronto con il trattamento con Pemetrexed. I pazienti coinvolti soffrono di NSCLC recidivante/di IV stadio in cui la malattia non e' progredita (crescita del tumore) dopo 4 cicli di trattamento chemioterapico con il Platino.I pazienti vengono assegnati in modo casuale ad uno dei due trattamenti, ma sapranno quale trattamento riceveranno
To compare overall survival of subjects who have been randomized to receive ipilimumab at 10mg/kg to that of subjects receiving pemetrexed at 500mg/m2. confrontare la sopravvivenza complessiva d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
3
4
5
6
7
8
9
10
11
12
Suivant